Melinta Therapeutics


Melinta Therapeutics, Inc. (MLNT) is the largest pure-play antibiotics company, dedicated to saving lives threatened by the global public health crisis of bacterial infections through the development and commercialization of novel antibiotics that provide new therapeutic solutions. Its four marketed products include Baxdela® (delafloxacin), Vabomere® (meropenem and vaborbactam), Orbactiv® (oritavancin), and Minocin® (minocycline) for Injection. This portfolio provides Melinta with the unique ability to provide providers and patients with a range of solutions that can meet the tremendous need for novel antibiotics treating serious infections. Visit for more information.

United States



Antimicrobials Antibiotics

View Employees

David Luke
National Director, Medical Affairs Directors at Melinta Therapeutics
Scott Pierce
National Account Director, Trade & GPO at Melinta Therapeutics
Don Matchett
Director, Learning & Development at Melinta Therapeutics
Alex Victalino
Director of Information Technology at Melinta Therapeutics
Karen Widuch
Sr. Supply Chain Mgr. at Melinta Therapeutics
Shanti Samuel
Medical Science Liaison (Anti-infectives, Southeast) at Melinta Therapeutics
Susan Blum
VP of Finance & Chief Accounting Officer at Melinta Therapeutics
Michelle Nickoli
Senior Director of Sales at Melinta Therapeutics

Find more contacts